Inhaled delivery offers unique advantages for exosome therapeutics, including:
Ideal for lung-related diseases such as asthma, COPD, ARDS, fibrosis, and viral respiratory infections.
Provides high local concentration with reduced systemic side effects.
Eliminates injectable routes, have the potential to improve patient compliance towards treatment, and supports at-home administration.
Nasal delivery enables fast uptake and the potential for nose-to-brain transport via the olfactory pathway.
Formulations are designed to preserve vesicle structure, bioactivity, and therapeutic performance throughout aerosol generation.
Spray-dried and freeze-dried exosomes minimize cold-chain reliance and simplify global distribution.
Esco Aster offers advanced formulation solutions for inhalation-based exosome delivery, enabling developers to transform exosome candidates into nasal spray, nebulizer-ready, or dry powder inhalation products. By integrating specialized particle engineering, stability studies, and aerosolization expertise, we support the development of inhaled exosome therapeutics designed for respiratory, neurological, and systemic indications.
Esco Aster formulates exosomes for nasal delivery, optimizing for efficient mucosal absorption and stability.
Available formats include:
This route supports rapid systemic uptake and potential nose-to-brain delivery.
Exosomes can be engineered for compatibility with common jet and mesh nebulizers, ensuring structural integrity and consistent aerosol performance.
Capabilities include:
Each formulation is optimized to withstand
aerosolization stress without compromising therapeutic potency.
For long-term stability and global distribution, Esco Aster offers advanced drying approaches:
These enable reduced cold-chain requirements and scalable manufacturing.
Format | Description | Use Case | Stability Profile |
|---|---|---|---|
Liquid
(Nasal) | Exosomes in buffered solution | Immediate-use nasal sprays | Refrigerated or frozen |
Freeze-Dried (Lyophilized) | Powder reconstituted upon use | Nebulizers, DPIs | Excellent long-term stability |
Spray-Dried | Dry powder with optimized particle size | Dry powder inhalers (DPIs) | High reconstitution yield, ambient stability |
Delivery Route | Onset of Action | Target Precision | Typical Use | Key Advantage |
|---|---|---|---|---|
| Nasal Spray | Rapid | High (mucosal & possibly brain) | Olfactory, systemic therapy | Non-invasive, fast absorption |
| Nebulization (Liquid) | Moderate | Local (lungs) | Pulmonary diseases | High lung deposition, scalable dosing |
| Dry Powder Inhalation | Variable (depends on breathing) | Local (lungs) or systemic | Chronic respiratory conditions | No cold chain, portable |
With deep expertise in exosome characterization, formulation science, and scalable processing including drug product fill & finish.
Esco Aster provides an integrated platform to advance inhalable exosome therapeutics from concept to clinic. Our team ensures product stability, regulatory readiness, and manufacturing feasibility to accelerate innovation in non-invasive biologic delivery.
Contact Esco Aster to explore how our inhalation exosome formulation services can support your therapeutic development needs.

Esco Aster Drug Product Fill & Finish for Aseptic Processing of Advanced Therapeutics